Search
Verastem Inc
VSTMAdd to Watchlist
6.580USD
-0.090-1.35%
Close 08-14 16:00（ET）Quotes delayed by 15 min
595.91MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Verastem Inc is 8.67, ranking 75 out of 387 in the Biotechnology & Medical Research industry. The average price target is 15.50, with a high of 20.00 and a low of 14.00.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
14.750
Target Price
+124.16%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Verastem Inc
VSTM
9
argenx SE
ARGX
28
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Verastem Inc's expected revenue for the next quarter?
Verastem Inc's expected revenue is 29.13M.
What is Verastem Inc's price target?
Analysts forecast that Verastem Inc's price target is USD 15.50, with the highest forecast at USD 20.00 and the lowest forecast at USD 14.00.
How have Verastem IncVSTM's recent earnings per share performed?
The market expectation was USD -0.35, while Verastem IncVSTM's earnings per share (EPS) for the previous quarter was USD -0.37. EPS for the next quarter is expected at USD -0.44.
What is the analyst rating for Verastem Inc?
Based on the ratings of Verastem Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.